{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:50:45Z","timestamp":1793742645234,"version":"4.6.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"am","delay-in-days":346,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.bulcan.2023.04.013","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T11:29:58Z","timestamp":1686914998000},"page":"937-949","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Diagnostic et prise en charge de la pneumopathie interstitielle diffuse induite par les anticorps conjugu\u00e9s dans le cancer du sein\u00a0: avis d\u2019expert"],"prefix":"10.1016","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1049-9661","authenticated-orcid":false,"given":"Luis","family":"Teixeira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Di\u00e9ras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Crestani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Lederlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Duchemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Pierga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Cadranel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2023.04.013_bib0235","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11864-019-0633-6","article-title":"Antibody-drug conjugates in breast cancer: a comprehensive review","volume":"20","author":"Ponde","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0240","first-page":"20","article-title":"HER2\u00a0directed antibody-drug-conjugates beyond T-DM1\u00a0in breast cancer","author":"Rinnerthaler","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0245","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1158\/1078-0432.CCR-19-3980","article-title":"FDA approval summary: ado-trastuzumab emtansine for the adjuvant treatment of HER2-positive early breast cancer","volume":"26","author":"Wedam","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0250","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1\u00a0dose-escalation and dose-expansion study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0255","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0260","unstructured":"Summary of the European public assessment report (EPAR) for Kadcyla (15\/11\/2013). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kadcyla."},{"key":"10.1016\/j.bulcan.2023.04.013_bib0265","unstructured":"Summary of the European public assessment report (EPAR) for Enhertu (18\/01\/2021). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/enhertu."},{"key":"10.1016\/j.bulcan.2023.04.013_bib0270","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1164\/rccm.202002-0360UP","article-title":"Update in Interstitial Lung Disease 2019","volume":"202","author":"Montesi","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0275","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.chest.2020.11.027","article-title":"Diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the Fleischner Society","volume":"159","author":"Johkoh","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0280","series-title":"Pooled analysis of drug-related interstitial lung disease (ILD) in 8\u00a0single-arm trastuzumab deruxtecan (T-DXd) studies. Presented at: AACR Annual Meeting","author":"Powell","year":"2021"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0285","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1001\/jamaoncol.2021.3595","article-title":"Interstitial lung disease induced by anti-ERBB2\u00a0antibody-drug conjugates: a review","volume":"7","author":"Tarantino","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0290","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1111\/cas.14686","article-title":"Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys","volume":"111","author":"Kumagai","year":"2020","journal-title":"Cancer Sci"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0295","first-page":"953","article-title":"Expression of the HER-2\/neu proto-oncogene in normal human adult and fetal tissues","volume":"5","author":"Press","year":"1990","journal-title":"Oncogene"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0300","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/j.jtho.2021.01.280","article-title":"Datopotamab deruxtecan (Dato-DXd; DS-1062), a TROP2\u00a0ADC, in patients with advanced NSCLC: updated results of TROPION-PanTumor01\u00a0phase 1\u00a0study","volume":"16","author":"Spira","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0305","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10549-020-05754-8","article-title":"Incidence of pneumonitis\/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer","volume":"183","author":"Hackshaw","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0310","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1200\/JCO.2013.54.4999","article-title":"Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis","volume":"32","author":"Dieras","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0315","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","article-title":"Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3\u00a0trial","volume":"15","author":"Krop","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0320","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejca.2018.12.022","article-title":"Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: primary results from the KAMILLA study cohort 1","volume":"109","author":"Montemurro","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0435","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0440","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.2016.67.4887","article-title":"Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study","volume":"35","author":"Perez","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0445","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","article-title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3\u00a0trial","volume":"19","author":"Hurvitz","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0325","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0450","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(20)30465-4","article-title":"Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial","volume":"21","author":"Emens","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0340","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS20-PD3-06","article-title":"Abstract PD3-06: updated results from DESTINY-breast01, a phase 2\u00a0trial of trastuzumab deruxtecan (T-DXd) in HER2\u00a0positive metastatic breast cancer","volume":"81","author":"Modi","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0455","series-title":"Presented at: SABCS; December 6\u201310, 2022","article-title":"Trastuzumab deruxtecan vs physician's choice in patients with HER2+ unresectable and\/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized phase 3\u00a0study DESTINY-Breast02","author":"Krop","year":"2022"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0330","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0230","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS20-PD3-07","article-title":"Abstract PD3-07: Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: a 2-part, phase 1b, multicenter, open-label study","volume":"81","author":"Hamilton","year":"2021","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.bulcan.2023.04.013_bib0345","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0355","doi-asserted-by":"crossref","first-page":"S1288","DOI":"10.1016\/j.annonc.2021.08.2088","article-title":"Primary outcome of the phase III SYD985. 002\/TULIP trial comparing [vic-] trastuzumab duocarmazine to physician's choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer","volume":"32","author":"Saura Manich","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0335","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0350","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS20-PD3-07","article-title":"Abstract PD3-07: trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: a 2-part, phase 1b, multicenter, open-label study","volume":"81","author":"Hamilton","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0360","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/1874306401206010063","article-title":"Drug induced interstitial lung disease","volume":"6","author":"Schwaiblmair","year":"2012","journal-title":"Open Respir Med J"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0365","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.resinv.2013.09.001","article-title":"Consensus statement for the diagnosis and treatment of drug-induced lung injuries","volume":"51","author":"Kubo","year":"2013","journal-title":"Respir Investig"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0415","doi-asserted-by":"crossref","first-page":"100404","DOI":"10.1016\/j.esmoop.2022.100404","article-title":"Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment","volume":"7","author":"Conte","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0370","doi-asserted-by":"crossref","first-page":"100554","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0375","unstructured":"Pneumotox online. The Drug-Induced Respiratory Disease Website. v2.2. https:\/\/www.pneumotox.com\/drug\/index\/."},{"key":"10.1016\/j.bulcan.2023.04.013_bib0380","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0385","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.rmr.2022.01.005","article-title":"[French practical guidelines for the diagnosis and management of IPF\u00a0\u2014\u00a02021\u00a0update, short version]","volume":"39","author":"Cottin","year":"2022","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0390","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0395","doi-asserted-by":"crossref","unstructured":"Spagnolo P., Bonniaud P., Rossi G., et al. Drug-induced interstitial lung disease. Eur Respir J 2022Oct 27;60(4):2102776. doi: 10.1183\/13993003.02776-2021. Print 2022 Oct. PMID: 35332071.","DOI":"10.1183\/13993003.02776-2021"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0400","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0405","article-title":"Enhertu (trastuzumab deruxtecan). Summary of product characteristics","year":"2021","journal-title":"Daiichi Sankyo Europe GmbH"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0410","doi-asserted-by":"crossref","first-page":"102378","DOI":"10.1016\/j.ctrv.2022.102378","article-title":"Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis-Focus on proactive monitoring, diagnosis, and management","volume":"106","author":"Swain","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0420","doi-asserted-by":"crossref","first-page":"100553","DOI":"10.1016\/j.esmoop.2022.100553","article-title":"Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer","volume":"7","author":"Rugo","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0425","series-title":"Summary of product characteristics","author":"Kadcyla (trastuzumab emtansine)","year":"2013"},{"key":"10.1016\/j.bulcan.2023.04.013_bib0430","doi-asserted-by":"crossref","DOI":"10.1177\/17534666221117002","article-title":"Immunomodulatory treatment of interstitial lung disease","volume":"16","author":"van den Bosch","year":"2022","journal-title":"Ther Adv Respir Dis"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123002084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123002084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T14:34:20Z","timestamp":1726151660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455123002084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0007455123002084"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.04.013","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic et prise en charge de la pneumopathie interstitielle diffuse induite par les anticorps conjugu\u00e9s dans le cancer du sein\u00a0: avis d\u2019expert","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}